5 result(s) displayed (1 - 5 of 5):
After it closes the $41.1 billion acquisition of Schering-Plough Corp. (NYSE:SGP), Merck & Co. (NYSE:MRK) will reorganize into five main units, with animal health and consumer healthcare operating as separate business units. The other divisions are global human health, manufacturing and Merck Research Laboratories. The company also will create new...
Posted on August 31, 2009 2:41 PM
Merck & Co. (NYSE:MRK) is selling its stake in its animal health joint venture Merial Ltd. to partner French drugmaker Sanofi-Aventis SA (NYSE:SNY) for $4 billion in cash. (The Deal Pipeline subscribers can get the details here.) But the partners might not be separated for long. Here's the story. Merck's exit...
Posted on July 30, 2009 8:45 AM
In a broader effort to focus on its human pharmaceutical business and raise cash (as well as investor confidence), Indian generic drug maker Wockhardt Ltd. is selling its animal health division to France's Vétoquinol. The deal marks Vétoquinol's entrance into India. Earlier this month, Wockhardt sold its German business Esparma...
Posted on June 29, 2009 3:29 PM
After about five months on the job, Sanofi-Aventis SA (NYSE:SNY) chief executive Chris Viehbacher is making his presence felt as the company reports profits are up about 16% and confirmed 2009 guidance.Viehbacher, on the hunt for acquisitions, cut 14 drugs in development from its pipeline of 65 -- including four...
Posted on April 29, 2009 2:53 PM
One of our Monday morning posts on the acquisition of Schering-Plough Corp. (NYSE:SGP) by Merck & Co. (NYSE:MRK) focused on the way the deal will bring Merck into consumer products and boost its presence in animal health, especially the high-growth business of high-tech searches for lost pets.There's since been a...
Posted on March 9, 2009 4:52 PM
Movable Type search results powered by Fast Search